CAMP
CAMP4 Therapeutics Corporation NASDAQ Listed Oct 11, 2024$4.37
Pre-mkt
$4.36
-0.23%
Mkt Cap $92.8M
52w Low $1.32
47.4% of range
52w High $7.75
50d MA $4.26
200d MA $4.32
P/E (TTM)
—
EV/EBITDA
—
P/B
2.8x
Debt/Equity
0.0x
ROE
-168.6%
P/FCF
-4.5x
RSI (14)
58.30
ATR (14)
$0.49
Beta
0.41
50d MA
$4.26
200d MA
$4.32
Avg Volume
237.3K
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
One Kendall Square Bldg 1400 West, 3rd Floor · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.31 | -0.87 | -180.6% | 4.59 | -2.6% | -8.5% | +49.5% | -3.7% | -7.4% | -3.9% | — |
| Nov 6, 2025 | AMC | -0.47 | -0.55 | -17.0% | 4.45 | -2.2% | -4.5% | -2.1% | -0.7% | +6.3% | -2.7% | — |
| Aug 14, 2025 | AMC | -0.67 | -0.62 | +7.5% | 1.55 | +0.0% | +7.7% | +11.4% | -8.1% | -9.9% | +3.2% | — |
| May 13, 2025 | AMC | -0.70 | -0.62 | +11.4% | 2.02 | +4.0% | -7.9% | +12.9% | +9.5% | -4.8% | +1.8% | — |
| Mar 27, 2025 | AMC | -0.91 | -2.83 | -211.0% | 4.42 | +12.9% | -2.9% | -6.8% | -3.5% | -8.5% | -12.5% | — |
| Oct 11, 2024 | AMC | -1.07 | -0.69 | +35.6% | 10.72 | +4.8% | -9.0% | +10.3% | +1.6% | -0.5% | +1.3% | — |
| Jul 8, 2024 | AMC | -0.92 | -1.61 | -75.0% | — | — | — | — | — | — | — | — |
| Jun 6, 2024 | AMC | -2.04 | -1.03 | +49.7% | — | — | — | — | — | — | — | — |
| Jan 9, 2024 | AMC | -2.30 | -3.91 | -70.0% | — | — | — | — | — | — | — | — |
| Oct 5, 2023 | AMC | -0.00 | -0.01 | -132.9% | — | — | — | — | — | — | — | — |
| Jul 10, 2023 | AMC | 0.92 | -0.23 | -125.0% | — | — | — | — | — | — | — | — |
| Apr 27, 2023 | AMC | 0.23 | 1.38 | +500.0% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16 | JP Morgan | Upgrade | Neutral → Overweight | $9 | $3.96 | $4.49 | +13.4% | +4.3% | +0.2% | -0.2% | +1.7% | +3.8% |
| Jun 10 | Chardan Capital Markets | Initiates | Buy | $6 | $4.01 | $4.11 | +2.5% | +8.2% | -2.8% | -0.7% | -5.5% | +4.3% |
| Apr 2 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.46 | $4.39 | -1.6% | +0.2% | +0.4% | +3.6% | -1.5% | -2.0% |
| Sep 16 | JP Morgan | Downgrade | Overweight → Neutral | — | $2.65 | $2.89 | +9.1% | +4.5% | -6.5% | -3.5% | -8.8% | +20.6% |
| Sep 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.25 | $3.16 | -2.8% | -18.5% | +4.5% | -6.5% | -3.5% | -8.8% |
| Jan 11 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 9 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 8 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 6 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 6 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 5 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 5 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 29 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 28 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 13 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Jul 12 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Jul 11 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 10 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 26 | Jefferies | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Jun 25 | Jefferies | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| May 1 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Apr 30 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Apr 28 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 27 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 18 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Apr 17 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 14 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 13 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Aug 16 | Craig-Hallum | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Aug 15 | Craig-Hallum | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Mar 25 | Jefferies | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 24 | Jefferies | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 22 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 21 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 21 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Jun 25 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 24 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 23 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 22 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 18 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 18 | JP Morgan | Downgrade | Neutral → Underweight | — | — | — | — | — | — | — | — | — |
| Dec 17 | JP Morgan | Downgrade | Neutral → Underweight | — | — | — | — | — | — | — | — | — |
| Apr 17 | Jefferies | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Apr 16 | Jefferies | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Mar 27 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 19 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 18 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 6 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 5.02
!!! Very High
CAMP4 Therapeutics Corporation -- 8-K 5.02: Executive Change
Jun 12
8-K · 7.01
! Medium
CAMP4 Therapeutics Corporation -- 8-K 7.01: Regulation FD Disclosure
CAMP4 Therapeutics presented preclinical data showing its CMP-002 candidate improves seizure outcomes in SYNGAP1-related disorder models, potentially supporting future clinical development.
May 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The appointment of an experienced biotech CFO with Biogen and Big Four audit background strengthens financial credibility, potentially signaling investor confidence and improving governance oversight at CAMP/PTCHF.
Mar 24
8-K · 7.01
! Medium
CAMP4 Therapeutics Corporation -- 8-K 7.01: Regulation FD Disclosure
Camp4 Therapeutics updated its corporate presentation on March 5, 2026, providing investors with refreshed business summaries available on its investor relations website.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 6,307,636 | $28M | New | Mar 2026 |
| 2 | Fmr Llc | 4,933,432 | $22M | — | Mar 2026 |
| 3 | Vivo Capital, Llc | 4,246,568 | $19M | New | Mar 2026 |
| 4 | Trails Edge Capital Partners, Lp | 1,939,563 | $9M | Reduced | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,534,768 | $7M | New | Mar 2026 |
| 6 | Stonepine Capital Management, Llc | 1,389,622 | $6M | Added | Mar 2026 |
| 7 | Susquehanna International Group, Llp | 336,047 | $1M | New | Mar 2026 |
| 8 | Two Sigma Investments, Lp | 108,875 | $480K | Added | Mar 2026 |
| 9 | Millennium Management | 85,918 | $379K | Added | Mar 2026 |
| 10 | Victory Capital Management Inc | 82,450 | $364K | — | Mar 2026 |
| 11 | Northern Trust Corp | 70,666 | $312K | Reduced | Mar 2026 |
| 12 | Jane Street Group, Llc | 25,534 | $157K | New | Dec 2025 |
| 13 | Barclays Plc | 34,693 | $153K | Reduced | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 31,196 | $138K | Added | Mar 2026 |
| 15 | Hrt Financial Lp | 30,747 | $135K | New | Mar 2026 |
| 16 | Citigroup Inc | 21,403 | $131K | New | Dec 2025 |
| 17 | Morgan Stanley | 19,828 | $122K | Added | Dec 2025 |
| 18 | Qube Research & Technologies Ltd | 24,803 | $109K | New | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 18,718 | $83K | — | Mar 2026 |
| 20 | Point72 Asset Management | 17,326 | $76K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Select Biotechnology Portfolio | 1,326,208 | $6M | Feb 2026 |
| 2 | Fidelity Growth Company Fund | 400,071 | $2M | Feb 2026 |
| 3 | Victory Science & Technology Fund | 227,800 | $843K | Jan 2026 |
| 4 | Fidelity Extended Market Index Fund | 150,844 | $677K | Feb 2026 |
| 5 | Fidelity Growth Company K6 Fund | 110,942 | $498K | Feb 2026 |
| 6 | Fidelity Series Growth Company Fund | 89,423 | $402K | Feb 2026 |
| 7 | iShares Micro-Cap ETF | 72,808 | $321K | Mar 2026 |
| 8 | Fidelity Total Market Index Fund | 61,034 | $274K | Feb 2026 |
| 9 | Fidelity Series Total Market Index Fund | 48,982 | $220K | Feb 2026 |
| 10 | Fidelity Nasdaq Composite Index Fund | 24,791 | $111K | Feb 2026 |
| 11 | Ultra-Small Company Market Fund | 25,000 | $110K | Mar 2026 |
| 12 | Victory Extended Market Index Fund | 1,858 | $7K | Jan 2026 |
Valuation
Market Cap
$92.8M
Enterprise Value
$24.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
6.16x
P/B
2.78x
P/S
23.59x
P/FCF
-4.45x
EV/EBITDA
—
Shares Out
30.4M
Financials (TTM)
Revenue
$3.9M
Net Income
-$86.3M
EBITDA
-$52.2M
Free Cash Flow
-$29.8M
Op Cash Flow
-$29.6M
EPS Basic
$-2.65
EPS Diluted
$-2.27
EPS Forward
$-0.78
Gross Margin
76.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$117.8M
Total Liab.
$70.1M
Total Equity
$47.7M
Cash
$109.5M
LT Debt
$1.7M
Book Value/Sh
$1.57
Debt/Equity
0.04x
Current Ratio
7.35
Quick Ratio
7.35
Returns & Growth
ROE
-168.6%
ROA
-68.2%
ROIC
-50.7%
Rev Growth YoY
+436.5%
EPS Growth YoY
+0.4%
Price Returns
2W
+10.4%
1M
+8.2%
3M
-2.0%
6M
-27.2%
12M
+223.7%
Technicals
52W High
$7.75
52W Low
$1.32
50d MA
$4.26
200d MA
$4.32
RSI (14)
58.30
ATR (14)
$0.49
Beta
0.41
Avg Volume
237K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.40
High
$18.00
Low
$5.00
Median
$10.00
Data updated apr 24, 2026 11:46pm
· Source: financialmodelingprep.com